Mohammadi S, Ravindra V, Gleich DF, Grama A. A geometric approach to characterize the functional identity of single cells. Nat Commun. 2018;9(1):1516. doi:10.1038/s41467-018-03933-2
Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-4. doi:10.1038/nature11183
Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355-63. doi:10.1158/2159-8290.CD-13-0310
Zhou P, Shaffer DR, Arias DAA, et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 2014;506(7486):52-7. doi:10.1038/nature12988
Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 2014;514(7520):54-8. doi:10.1038/nature13556
McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16(8):717-27. doi:10.1038/ncb3015
Dey-Guha I, Alves CP, Yeh AC, Sole X, Darp R, Ramaswamy S. A mechanism for asymmetric cell division resulting in proliferative asynchronicity. Mol Cancer Res. 2015;13(2):223-30. doi:10.1158/1541-7786.MCR-14-0474
Wang H, Yu C, Gao X, et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015;27(2):193-210. doi:10.1016/j.ccell.2014.11.017
Majumder B, Baraneedharan U, Thiyagarajan S, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015;6:6169. doi:10.1038/ncomms7169
Kim D, Fiske BP, Birsoy K, et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 2015;520(7547):363-7. doi:10.1038/nature14363